A previously unidentified mineralocorticoid, 16β-hydroxydehydroepiandrosterone (16β OH-DHEA) has recently been isolated from urine extracts of patients with low-renin hypertension and reported to possess one-fortieth the mineralocorticoid potency of aldosterone by bioassay. However, using a radioreceptor assay, we demonstrate the affinity of 16β-OH-DHEA for renal 3H-aldosterone receptors to be only 0.011 per cent that of unlabeled aldosterone. 16β-OH-DHEA therefore would not be expected to possess significant mineralocorticoid properties unless its mechanism of action involves binding to a unique class of renal receptors. Until these discrepancies between bioassayable mineralocorticoid activity and affinity for mineralocorticoid receptors can be resolved, the role of 16β-OH-DHEA in the pathogenesis of low-renin hypertension remains speculative.
|Original language||English (US)|
|Number of pages||7|
|Journal||The Journal of Laboratory and Clinical Medicine|
|State||Published - Feb 1977|
ASJC Scopus subject areas
- Pathology and Forensic Medicine